Enhanced oral bioavailability of paclitaxel by solid dispersion granulation

Drug Development and Industrial Pharmacy

Volumn 41, Issue 11, 2015, Pages 1864-1876

  Shanmugam, Srinivasan ^a   Im, Ho Taek ^a,b   Sohn, Young Taek ^c   Kim, Yong Il ^a   Park, Jae Hyun ^a   Park, Eun Seok ^b   Woo, Jong Soo ^a  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Duksung Women's University   (South Korea)

Author keywords

Dissolution; Fluid bed; HM38101; Oral bioavailability; Paclitaxel; Solid dispersion granules; Spray drying

Indexed keywords

PACLITAXEL; POLYSORBATE 80; 4-OXO-4H-CHROMENE-2-CARBOXYLIC ACID (2-(2-(4-(2-(6,7-DIMETHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHYL)-PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)AMIDE; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; ISOQUINOLINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; TABLET; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DOG; DRUG BIOAVAILABILITY; DRUG GRANULATION; DRUG GRANULE; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; SPRAY DRYING; STOMACH JUICE; TABLET FRIABILITY; TABLET HARDNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; COMPARATIVE STUDY; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TABLET;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZOPYRANS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG LIBERATION; ISOQUINOLINES; MALE; P-GLYCOPROTEIN; PACLITAXEL; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TETRAZOLES;

EID: 84979610025     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1018275     Document Type: Article

References (64)

1. Wall ME. Camptothecin and taxol: discovery to clinic. Med Res Rev 1998;18:299–314
2. Wall ME, Wani MC. Camptothecin and taxol: from discovery to clinic. J Ethnopharmacol 1996;51:239–53 (discussion 53–4)
3. Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995;13:381–404
4. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Sem Oncol 1992;19:646–62
5. Hawkins MJ. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles. Oncology (Williston Park) 1992;6:17–23 (discussion 7–30)
6. Zhang Z, Mei L, Feng SS. Paclitaxel drug delivery systems. Expert Opin Drug Deliv 2013;10:325–40
7. Hackett MJ, Joolakanti S, Hartranft ME, et al. A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery. J Pharm Sci 2012;101:3292–304
8. Rowinsky EK. Clinical pharmacology of Taxol. J Natl Cancer Inst Monogr 1993;2:25–37
9. Veltkamp SA, Thijssen B, Garrigue JS, et al. A novel selfmicroemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 2006;95:729–34.
10. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004;21:261–70.
11. Ahmad J, Mir SR, Kohli K, et al. Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and gamma scintigraphy imaging. BioMed Res Int 2014;2014: 984756.
12. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 2010;99:4630–41.
13. Tiwari SB, Amiji MM. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 2006;6:3215–21.
14. Zhao Y, Li Y, Ge J, et al. Pluronic-poly (acrylic acid)-cysteine/ Pluronic L121 mixed micelles improve the oral bioavailability of paclitaxel. Drug Dev Ind Pharm 2014;40:1483–93.
15. Kim S, Kim JY, Huh KM, et al. Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Control Release 2008;132:222–9.
16. Yao HJ, Ju RJ, Wang XX, et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011;32:3285–302.
17. Patel K, Patil A, Mehta M, et al. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. Int J Pharm 2014;472: 214–23.
18. Deng L, Su TT, Huang XL, et al. Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route. Acta Pharm Sin 2014;49: 106–14.
19. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 2012;33:6758–68.
20. Battogtokh G, Ko YT. Self-assembled chitosan-ceramide nanoparticle for enhanced oral delivery of paclitaxel. Pharm Res 2014;31: 3019–30.
21. Zhao L, Feng SS. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci 2010; 99:3552–60.
22. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol 2005;1:755–62.
23. Groo AC, Saulnier P, Gimel JC, et al. Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int J Manomedicine 2013;8:4291–302.
24. Peltier S, Oger JM, Lagarce F, et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 2006;23:1243–50.
25. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 2010;99:2049–60.
26. Sonar PA, Behera AL, Banerjee SK, et al. Preparation and characterization of Simvastatin solid dispersion using skimmed milk. Drug Dev Ind Pharm 2015;41:22–7.
27. Lin SP, Hou YC, Liao TY, Tsai SY. Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone. Drug Dev Ind Pharm 2014;40:330–7.
28. Dave RH, Patel HH, Donahue E, Patel AD. To evaluate the change in release from solid dispersion using sodium lauryl sulfate and model drug sulfathiazole. Drug Dev Ind Pharm 2013;39:1562–72.
29. Jang DJ, Sim T, Oh E. Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption. Drug Dev Ind Pharm 2013;39:1133–41.
30. Park JH, Yan YD, Chi SC, et al. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. J Pharm Pharmacol 2011;63:491–9.
31. Shanmugam S, Park JH, Chi SC, et al. Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process. Drug Dev Ind Pharm 2011;37:628–37.
32. Shanmugam S, Park JH, Chi SC, et al. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts. Int J Pharm 2011;403:130–5.
33. Kim YI, Kim KS, Suh KH, et al. New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs. Int J Pharm 2011;415:129–39.
34. Rambharose S, Ojewole E, Branham M, et al. High-energy ball milling of saquinavir increases permeability across the buccal mucosa. Drug Dev Ind Pharm 2014;40:639–48.
35. Nekkanti V, Marwah A, Pillai R. Media milling process optimization for manufacture of drug nanoparticles using design of experiments (DOE). Drug Dev Ind Pharm 2015;41:124–30.
36. Chen C, Xie X, Li Y, et al. Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions. Drug Dev Ind Pharm 2014;40:441–51.
37. Moes J, Koolen S, Huitema A, et al. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur J Pharm Biopharm 2013;83:87–94.
38. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 2008;70:493–9.
39. Porter TM, Crum LA, Stayton PS, Hoffman AS. Effect of polymer surface activity on cavitation nuclei stability against dissolution. J Acoust Soc Am 2004;116:721–8.
40. Miyazaki T, Yoshioka S, Aso Y, Kojima S. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J Pharm Sci 2004;93:2710–17.
41. Aso Y, Yoshioka S, Zhang J, Zografi G. Effect of water on the molecular mobility of sucrose and poly(vinylpyrrolidone) in a colyophilized formulation as measured by (13)C-NMR relaxation time. Chem Pharm Bull 2002;50:822–6.
42. Oksanen CA, Zografi G. The relationship between the glass transition temperature and water vapor absorption by poly(vinylpyrrolidone). Pharm Res 1990;7:654–7.
43. Aso Y, Yoshioka S. Molecular mobility of nifedipine-PVP and phenobarbital-PVP solid dispersions as measured by 13C-NMR spin-lattice relaxation time. J Pharm Sci 2006;95:318–25.
44. Desai SJ, Singh P, Simonelli AP, Higuchi WI. Investigation of factors influencing release of solid drug dispersed in inert matrices Quantitative studies involving the polyethylene plastic matrix. J Pharm Sci 1966;55:1230–4.
45. Higuchi T. Mechanism of sustained-action medication. theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145–9.
46. Gil EC, Colarte AI, Bataille B, et al. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm 2006;317:32–9.
47. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Mucoadhesive delivery systems. II. Formulation and in-vitro/in-vivo evaluation of buccal mucoadhesive tablets containing water-soluble drugs. Drug Dev Ind Pharm 2004;30:995–1004.
48. Quadir MA, Chanda E, Haider SS, et al. Evaluation of ethylcellulose as matrices for controlled release drug delivery. Pak J Pharm Sci 2005;18:29–34.
49. Dhiman M, Yedurkar P, Sawant KK. Formulation, characterization, and in vitro evaluation of bioadhesive gels containing 5-Fluorouracil. Pharm Dev Technol 2008;13:15–25.
50. Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 1972;24:979–81.
51. Ray S, Maiti S, Sa B. Polyethyleneimine-treated xanthan beads for prolonged release of diltiazem: in vitro and in vivo evaluation. Arch Pharm Res 2010;33:575–83.
52. Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm 2004;280:221–7.
53. Hong JW, Lee IH, Kwak YH, et al. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther 2007;6: 3239–47.
54. Nornoo AO, Zheng H, Lopes LB, et al. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009;71:310–17.
55. Feng Z, Zhao G, Yu L, et al. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol 2010;65:923–30.
56. Malingre MM, Beijnen JH, Rosing H, et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001;84:42–7.
57. Terwogt MJM, Beijnen JH, ten Bokkel Huinink WW, et al. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 1998;352:285.
58. Paek IB, Ji HY, Kim MS, et al. Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 2006;20: 1457–62.
59. Kim TE, Lee H, Lim KS, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol 2014;78:556–64.
60. Cha YJ, Lee H, Gu N, et al. Sustained increase in the oral bioavailability of loperamide after a single oral dose of HM30181, a P-glycoprotein inhibitor, in healthy male participants. Basic Clin Pharmacol Toxicol 2013. [Epub ahead of print]. doi: 10.1111/bcpt.12108.
61. Kim TE, Gu N, Yoon SH, et al. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies. Clin Ther 2012;34:482–94.
62. Bauer F, Wanek T, Mairinger S, et al. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol 2012;696:18–27.
63. Kwak JO, Lee SH, Lee GS, et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010;627:92–8.
64. Li H, Hardy RJ, Gu X. Effect of drug solubility on polymer hydration and drug dissolution from polyethylene oxide (PEO) matrix tablets. AAPS PharmSciTech 2008;9:437–43